184 related articles for article (PubMed ID: 36858526)
1. Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs.
Ono A; Kurihara R; Terada K; Sugano K
Chem Pharm Bull (Tokyo); 2023; 71(3):213-219. PubMed ID: 36858526
[TBL] [Abstract][Full Text] [Related]
2. Application of the BCS biowaiver approach to assessing bioequivalence of orally disintegrating tablets with immediate release formulations.
Ono A; Sugano K
Eur J Pharm Sci; 2014 Nov; 64():37-43. PubMed ID: 25151946
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
4. Utility of Physiologically Based Biopharmaceutics Modeling (PBBM) in Regulatory Perspective: Application to Supersede f2, Enabling Biowaivers & Creation of Dissolution Safe Space.
Bhattiprolu AK; Kollipara S; Ahmed T; Boddu R; Chachad S
J Pharm Sci; 2022 Dec; 111(12):3397-3410. PubMed ID: 36096285
[TBL] [Abstract][Full Text] [Related]
5. Effect of the Similarity of Formulations and Excipients of Approved Generic Drug Products on In Vivo Bioequivalence for Putative Biopharmaceutics Classification System Class III Drugs.
Ren P; Chan T; Yang WC; Frost M; Wang Y; Luke M; Kim MJ; Lionberger R; Zhang Y
Pharmaceutics; 2023 Sep; 15(9):. PubMed ID: 37765334
[TBL] [Abstract][Full Text] [Related]
6. Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help.
Wu F; Cristofoletti R; Zhao L; Rostami-Hodjegan A
Biopharm Drug Dispos; 2021 Apr; 42(4):118-127. PubMed ID: 33759204
[TBL] [Abstract][Full Text] [Related]
7. Investigating the Discriminatory Power of BCS-Biowaiver in Vitro Methodology to Detect Bioavailability Differences between Immediate Release Products Containing a Class I Drug.
Colón-Useche S; González-Álvarez I; Mangas-Sanjuan V; González-Álvarez M; Pastoriza P; Molina-Martínez I; Bermejo M; García-Arieta A
Mol Pharm; 2015 Sep; 12(9):3167-74. PubMed ID: 26287948
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
9. BCS-based biowaivers: Extension to paediatrics.
Martir J; Flanagan T; Mann J; Fotaki N
Eur J Pharm Sci; 2020 Dec; 155():105549. PubMed ID: 32941998
[TBL] [Abstract][Full Text] [Related]
10. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Isavuconazonium Sulfate.
Plano D; Rudolph N; Saal C; Abrahamsson B; Cristofoletti R; Kambayashi A; Langguth P; Mehta M; Parr A; Polli JE; Shah VP; Charoo N; Dressman J
J Pharm Sci; 2024 Feb; 113(2):386-395. PubMed ID: 37951471
[TBL] [Abstract][Full Text] [Related]
11. In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen.
Tsume Y; Langguth P; Garcia-Arieta A; Amidon GL
Biopharm Drug Dispos; 2012 Oct; 33(7):366-77. PubMed ID: 22815122
[TBL] [Abstract][Full Text] [Related]
12. Investigation to Explain Bioequivalence Failure in Pravastatin Immediate-Release Products.
Ruiz-Picazo A; Colón-Useche S; Perez-Amorós B; González-Álvarez M; Molina-Martínez I; González-Álvarez I; García-Arieta A; Bermejo M
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31835294
[TBL] [Abstract][Full Text] [Related]
13. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet.
Cheng CL; Yu LX; Lee HL; Yang CY; Lue CS; Chou CH
Eur J Pharm Sci; 2004 Jul; 22(4):297-304. PubMed ID: 15196586
[TBL] [Abstract][Full Text] [Related]
14. Theoretical Investigation of Dissolution Test Criteria for Waiver of Clinical Bioequivalence Study.
Sugano K
J Pharm Sci; 2016 Jun; 105(6):1947-1951. PubMed ID: 27238491
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates.
Kortejärvi H; Urtti A; Yliperttula M
Eur J Pharm Sci; 2007 Feb; 30(2):155-66. PubMed ID: 17187967
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Differences in Dosage Form Performance of Generics Using BCS-Based Biowaiver Specifications and Biopharmaceutical Modeling-Case Examples Amoxicillin and Doxycycline.
Hofsäss MA; Dressman J
J Pharm Sci; 2020 Aug; 109(8):2437-2453. PubMed ID: 32339527
[TBL] [Abstract][Full Text] [Related]
17. Biowaiver monograph for immediate-release solid oral dosage forms: fluconazole.
Charoo N; Cristofoletti R; Graham A; Lartey P; Abrahamsson B; Groot DW; Kopp S; Langguth P; Polli J; Shah VP; Dressman J
J Pharm Sci; 2014 Dec; 103(12):3843-3858. PubMed ID: 25312492
[TBL] [Abstract][Full Text] [Related]
18. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.
Charoo NA; Abdallah DB; Parveen T; Abrahamsson B; Cristofoletti R; Groot DW; Langguth P; Parr A; Polli JE; Mehta M; Shah VP; Tajiri T; Dressman J
J Pharm Sci; 2020 Sep; 109(9):2654-2675. PubMed ID: 32534881
[TBL] [Abstract][Full Text] [Related]
19. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
20. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of
Zhang S; Fang M; Zhang Q; Li X; Zhang T
Drug Dev Ind Pharm; 2019 Oct; 45(10):1646-1653. PubMed ID: 31342807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
